Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEXIC: Omalizumab for severe IgE-mediated asthma with high-dose corticosteroids
2016-004315-13Phase 4
- Sponsor
- Novartis
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of omalizumab in allergic asthma and asthma (2 arms), sponsored by Novartis. Primary endpoint: Number of patients able to reduce baseline budesonide/formoterol dose.
02
Drugs
omalizumab
03
Conditions
allergic asthmaasthma
Beyond the preview
Go deeper on 2016-004315-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004315-13.